Last reviewed · How we verify
rheumatoid arthritis ra
Approved treatments
Clinical guidelines
- FDA label — 1L
TOFIDENCE (tocilizumab-bavi) is indicated for the treatment of active systemic juvenile idiopathic arthritis in patients 2 years of age and older. - FDA label — 2L
TOFIDENCE (tocilizumab-bavi) is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more Disease-Modifying Anti-Rheumatic Drugs (DMARDs). - FDA label — 1L
TOFIDENCE (tocilizumab-bavi) is indicated for the treatment of giant cell arteritis (GCA) in adult patients. - FDA label — 1L
TOFIDENCE (tocilizumab-bavi) is indicated for the treatment of active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older. - FDA label — adjunctive
TOFIDENCE (tocilizumab-bavi) is indicated for the treatment of coronavirus disease 2019 (COVID-19) in hospitalized adult patients who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO).
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- rheumatoid arthritis ra patent landscape — cliff calendar, originator estates, attackable patents
- rheumatoid arthritis ra treatment landscape brief
- rheumatoid arthritis ra treatment updates RSS
Frequently asked questions about rheumatoid arthritis ra
What are the treatment guidelines for rheumatoid arthritis ra?
FDA label publishes guidelines for rheumatoid arthritis ra. 5 guideline references tracked.
Related
- Treatment landscape: rheumatoid arthritis ra patent cliff · rheumatoid arthritis ra CI report
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing